Fig. 2From: Metabolomic changes related to airway inflammation, asthma pathogenesis and systemic activity following inhaled fluticasone furoate/vilanterol: a randomized controlled trialStudy design. FF/VI, fluticasone furoate/vilanterol trifenatate; SABA, short-acting β2-agonist; T1, baseline; T2, Day 15; T3, Day 21Back to article page